Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
3.110
-0.110 (-3.42%)
At close: Nov 13, 2026, 4:00 PM EST
2.900
-0.210 (-6.75%)
Pre-market: Nov 16, 2026, 4:56 AM EST
← View all transcripts

3rd Annual Guggenheim Healthcare Innovation Conference

Nov 9, 2026

Summary

EB613 met Phase II biomarker and BMD endpoints, and FDA alignment supports a 12-month placebo-controlled Phase III study plus a 12-month extension. A $27.5 million PIPE is intended to fund the program through PDUFA, with runway into 2030.

Vamil Divan
Analyst, Guggenheim

Here at Guggenheim. Next up in this room, we have Entera Bio, and we have the CEO, Miranda Toledano. Exciting story, exciting company we just launched coverage on not too long ago, so thanks so much for joining us. Miranda, maybe just to kind of kick things off for people who don't know Entera, maybe just a little bit about the background of the company and kind of where things stand right now, and then we'll dive deeper into your programs.

Miranda Toledano
CEO, Entera Bio

Thank you very much, Vamil, for having me, and to your team. Entera is a company that's focused on developing first-in-class oral peptide therapeutics. We have a pipeline today which targets PTH(1-34) in two therapeutic indications, both endocrinology-focused, one very large, osteoporosis, and one rare disease, hypoparathyroidism. We also have programs in GLP-1 glucagon and GLP-2. Our lead clinical asset, we call EB613, is the first oral PTH(1-34) peptide in late-stage development for osteoporosis.

Vamil Divan
Analyst, Guggenheim

Okay, great. Perfect. On EB613, maybe, you're obviously getting close to starting your phase III program now. Maybe you can review for people the data you've generated on this asset to date and kind of the progress you've made to getting to this point.

Miranda Toledano
CEO, Entera Bio

EB613 has the exact same amino acid sequence as Forteo, which has been approved by Lilly for 24 years now under the name Forteo, Forsteo in Europe. The API is teriparatide, the functional region of the parathyroid hormone, which is a mainstay treatment for osteoporosis. EB613, because we share the exact same API as Forteo, is pursuing a 505(b)(2) application with the FDA. However, we have a very robust kind of clinical and even preclinical program for a 505(b)(2) application. We have six-month rat and nine-month non-human primate toxicology studies. We have three phase I safety and PK studies where the same participants received EB613, our tablet, or tablets, and Forteo at separate visits, and we monitor both PD, PK, and safety outcomes. Our phase II was specifically, of course, in postmenopausal women with low bone mass and osteoporosis.

That was a 161 placebo-controlled dose-ranging study where we looked at 0.5 mg up to 2.5 mg of EB613 daily, which met both biomarker as well as BMD endpoints, and that is published. Then we also have a similar formulation where we had a proof of concept phase II study in hypopara patients, which of course is a different disease, but that was dosed up to 9 mg a day, and also makes We have it as part of our safety database.

Vamil Divan
Analyst, Guggenheim

Okay.

Miranda Toledano
CEO, Entera Bio

So we have 270 subjects exposed to EB613 to date.

Vamil Divan
Analyst, Guggenheim

Okay. No, that is great. So one question I think that comes up sometimes, incorrectly, is the osteoporosis market. There has been a lot of development of new drugs in this market for a long time.

Miranda Toledano
CEO, Entera Bio

There has not.

Vamil Divan
Analyst, Guggenheim

No, historically there was none.

Miranda Toledano
CEO, Entera Bio

Oh, yes.

Vamil Divan
Analyst, Guggenheim

There's still obviously a lot of unmet need. Maybe you can just talk about what do you see as the unmet need, what are the current therapy options not providing to patients, and where does EB613 come in to try and address that need?

Miranda Toledano
CEO, Entera Bio

Where to begin? Okay. I describe osteoporosis as the most diagnosed yet undertreated chronic progressive condition globally. We're talking about 200 million women. This is a woman-centric disorder, so women are most at risk of developing osteoporosis, because estrogen declines during the menopause transition, and that creates rapid bone loss and a susceptibility to fracture. With the currently available drugs, and again, there hasn't been a new drug approved for seven years now, and there hasn't been a phase III for close to a decade, we estimate that a vast majority of patients do not have access or do not accept the currently available drugs. The currently available drugs basically fall into two main buckets. One of them are the antiresorptive drugs, and those are most commonly the bisphosphonates and Prolia, denosumab, the anti-RANKL monoclonal antibody.

We estimate about 80% of prescriptions go towards those two sub-buckets, the vast majority bisphosphonates. Not surprisingly, this is a silent and asymptomatic condition, so it is much easier for a woman or man to agree to get onto an oral agent once diagnosed. Antiresorptive drugs do not rebuild bone, and more importantly, they do not ameliorate the skeletal microarchitecture decay that happens in osteoporosis in contrast to anabolic drugs like PTH agonists, romosozumab, the three approved injectable anabolics, and hopefully EB613. The limitations to the current anabolics, however, even though they have superior efficacy and potential disease-modifying attributes, is that they are accessible or accepted by a minority of patients for different reasons, including cost, including mode of administration, and including different access limitations.

There is a white space in osteoporosis, and the FDA itself, in its qualification of the bone mineral density endpoint, notes the need for novel agents in this severe condition.

Vamil Divan
Analyst, Guggenheim

Okay. How are you seeing the market opportunity now for EB613? Obviously, we will see what the phase III data shows at the end of the day, but a sense of the patient numbers that you think you may be able to address in this big white space that is there.

Miranda Toledano
CEO, Entera Bio

Well, our thesis for EB613 is to provide a viable anabolic or bone-building treatment option to a much wider number of patients than are currently served by any of the existing anabolic injectables. We are looking to close the gap between the 60% that start on a bisphosphonate, and very quickly, about 50% discontinue due to acid reflux side effects and other reasons, and the less than 15%, one-five, minority of patients that get onto an anabolic. So, what we are looking to do is provide an oral option that will be able to rapidly increase bone mass and strength, be able to ameliorate the skeletal architecture, and be reasonable for, again, a vibrant postmenopausal woman or man that develops osteoporosis to agree to take at diagnosis.

And that may be a patient that's sitting across a GP, a family doctor, a gynecologist, an endocrinologist, a rheumatologist, or an an orthopedic surgeon. One of the biggest issues with this therapeutic indication, at least in the U.S., is that it's treated by a very kind of disparate healthcare ecosystem. Again, an oral agent, we believe, will be able to include patients that are treated at all of those different healthcare provider groups.

Vamil Divan
Analyst, Guggenheim

Okay, great. You've obviously had a lot of constructive discussion with the FDA over the last many years. Maybe you can just kind of summarize that for us now, where things stand in terms of the FDA's buy-in on BMD as a surrogate endpoint, and then on your phase III design that you're looking to start here shortly.

Miranda Toledano
CEO, Entera Bio

Well, BMD is the gold standard diagnostic patient stratification and management tool since the late 1980s. I've been probably one of the biggest advocate of the SABRE and FNIH work, the meta-analysis that led to the qualification of BMD as an efficacy endpoint, which can be used in place of fracture outcomes, which have really paralyzed innovation in this space for the past 10- 15 years. BMD has a much higher correlation to event-driven fracture outcomes than most surrogate endpoints that are used commonly today, like blood pressure for hypertension, which has an R-squared of about 0.37, I believe, and BMD has an R-squared of 0.73. So, in relation to the FDA, we have, again, a 505(b)(2), and we are not a bioidentical to Forteo. We have comparability. We have the same API.

We were looking to leverage on this qualification of the BMD, total hip BMD specifically, in a placebo-controlled phase III study, which FDA, in principle, agreed to across different dialogues since 2022. We had a big win in 2025 when the FDA, in an unprecedented manner, wrote in our minutes that we could use total hip BMD in a placebo-controlled format. At that point, we were still thinking about running a 24-month placebo-controlled study, and then we streamlined the proposed plan in 2026. In June of 2026, we announced the FDA had aligned with our ability to conduct a 12-month placebo-controlled study for EB613, followed with, they agreed that we would carry out an extension study for an additional 12 months, where we would collect, of course, safety and durability of response data on EB613 for a second year.

And then, of course, we have our scientific bridge analysis with Forteo, which is predicated on a PK exposure analysis. That is the culmination of seven different interactions with this division since 2022, and we are very happy to have alignment on this much more streamlined plan.

Vamil Divan
Analyst, Guggenheim

Okay. Then I guess just from your level of confidence on your clinical program, obviously, the phase II, you had positive results there, but it was a relatively smaller trial.

Miranda Toledano
CEO, Entera Bio

Yeah.

Vamil Divan
Analyst, Guggenheim

Now it is a much bigger phase III that you are moving into. So what is it about your data to date and kind of how you are planning the phase III that gives you confidence you will show similar sort of results?

Miranda Toledano
CEO, Entera Bio

Well, we are not looking at a novel molecule where we are kind of scratching our heads as to the safety and efficacy potential signal. We know teriparatide, and we can look at the data. Specifically, in our phase II EB613, because we showed a dual mechanism whereby we preferentially seem to, based on our biomarker profile anabolic window, preferentially activate osteoblast with actual suppression of osteoclast cells. We seem to have a much, much, much less cortical porosity and quicker onset of action at cortical bone sites like hip. This is really important because, of course, total hip BMD was shown to have the highest correlation and predictive value in terms of skeletal site measured by BMD to fracture outcomes.

We actually show a quicker onset of action, it seems, at six months on the hip, showing between 1.34%- 1.56% on total hip BMD with EB613 at six months. In relation to our data set in the phase II, just like to remind you that it is quite common in osteoporosis studies, when there haven't been many in the last decade, but if we look at other companies, I believe abaloparatide, Radius had about 33 completing its dose that they carried into the phase III, the commercial dose that's approved today. That jumps from their phase II in that dose was 43, but 33 completing, and they jumped into about 800 in that arm for the phase III. Romosozumab had 51 in that phase II at the dose that they brought into FRAME, and that was 3,200 women. Those are big jumps.

Forteo never published its phase II, so we can't provide that. We have 21 with a known API moving into about 600, so that's not so unusual.

Vamil Divan
Analyst, Guggenheim

Okay. Now maybe talking, switching back to the commercial sort of side of things in this market, there are obviously some of these older products that are generics now. How are you thinking about payer acceptance for a novel branded therapy? Would they need to go through the generics first, or can they start with this? Also kind of anything you could share, I know it's early, but just around pricing or how you think you'd have to price something like this for good access?

Miranda Toledano
CEO, Entera Bio

There are three buckets of generics today. I'm not sure which of them you're referring to, but maybe I'll try to. Forteo itself is generic since 2018. It is a very difficult peptide to replicate. It's very short-acting, and BONSITY in the U.S., which received, I believe, the fastest approval, actually had to require a 505(b)(2), even with the injection. Those generic or 505(b)(2) equivalents of Forteo are not cheap. These are still injectables. They range at about $14,000-$16,000 in the U.S. That's how Radius priced in line in 2018, I believe, abalo. Romosozumab is about $24,000. The PTH agonists have not increased the prescriptions. It's not a case of a generic small molecule where a generic comes in and suddenly there's a burst of patients that can access it finally.

We do not view that as a problem or a potential limitation in relation to access. Then we have the bisphosphonates, which have been generics for many years and cost about $1 a day. We know from the work that we've done that most drugs require a pass-through, a step-through bisphosphonate, and that includes drugs, we believe, even such as Prolia, denosumab. So we kind of bake that into our thinking. We also know that, as I mentioned, about 50% of patients discontinue bisphosphonates within 12 months, and that's within 12 months, if not sooner. There's a very rapid anyway line, second line post-bisphosphonate. That's the second bucket of generics, which are cheap. Then the third line of generics today are the denosumab generics.

Prolia started undergoing genericization in 2024, and there's every company in the world developing or have a biosimilar on Prolia. Again, these are antibodies, so it's the usual pricing of a biosimilar antibody. It's not going down to 80% of the branded drug. It goes down by 20%, 30%. We view Prolia as kind of an island. We don't look to cannibalize the Prolia. About 20%, 20% of prescriptions, I believe, we estimate go to Prolia. Prolia, again, is not an anabolic. It's a very potent antiresorptive. Prolia also has a clinical rebound that happens.

We are trying to bring EB613 also to younger women that travel and give more flexibility to have treatment versus Prolia, where you really should be taking that injection every six months on time to avoid kind of potential of multiple vertebral fractures, which happen if you are not good about taking your Prolia on time.

Vamil Divan
Analyst, Guggenheim

Okay, so we have a few more minutes here, so maybe we can just touch quickly on going beyond EB613. You obviously have other programs in development. Just kind of your highlights from the rest of your pipeline beyond EB613 as we look forward.

Miranda Toledano
CEO, Entera Bio

Beyond EB613, EB612 is our, hopefully, next to clinic. It is also PTH(1-34) directed, but this is a novel oral peptide. It is an acylated PTH(1-34) variant. We are co-developing it with our partner, OPKO. Specifically, this is being developed as a protein replacement therapy for patients with hypoparathyroidism, which is a very well-characterized therapeutic indication with Ascendis, and has a daily PTH pegylated injection, and MBX potentially coming in with a weekly. Septerna has a small molecule approach, and we are looking to come in to clinic, hopefully in 2027, with the oral peptide. So far what we have seen is that our variant is very potent. We expect to have potential very low milligram dosing. The top dose for EB613 is 3 mg, and we do not know yet, but we expect eb612 to be a very low single-digit potential dose.

There are differences between a small molecule approach versus an oral peptide specific to DDI and other limitations of small molecules. What we are planning at the moment is to finalize our IND-enabling steps, and then we have designed a phase I PK single ascending dose study, which we hope to initiate in 2027.

Vamil Divan
Analyst, Guggenheim

Okay. Okay, great. Maybe shifting gears again. You talk about women's health, you are talking about oral peptide delivery. These are sort of buzzwords, I feel like, in the industry right now with a lot of attention in these areas. I am curious, maybe you can just give us your perspective as a CEO, kind of how you see the future of Entera beyond sort of getting the phase III up and running here, just in terms of interest from strategics, interest in your platform. I know there is limitations on what you can share, but just how you are viewing sort of the next two to three years for the company.

Miranda Toledano
CEO, Entera Bio

Strategically, Entera, I mean, our lead asset, EB613, we need to move into phase III, and that is what we are working very hard on at the moment. EB612 hopefully will be very interesting as it gets into clinic, because we believe we have a very promising and potentially also disease-modifying asset in EB612 for hypoparathyroidism. In relation to N-Tab and our platform, I think we were very much under the radar in this rebuild in the last four years, and the focus was really to fix, remedy, build, evolve. I think given the transformational kind of financing, which was the culmination of that work in July, and EB613 potentially moving into phase III, it kind of, I think, put us on the radar for platform discussions, and that is great. In terms of oral peptide, I think a lot of companies are using this narrative or terminology.

We view what we do to be very focused on pure peptide, and that we're really just using native sequences that we have endogenously with no modification or basically acylation, which is an increased half-life. We're not using a medicinal chemistry approach like certain companies do. This is really oral peptide, and I think the closest comparable really is Novo's work with Ozempic and Wegovy tablet, which is also a GLP-1 acylated peptide.

Vamil Divan
Analyst, Guggenheim

Okay. Last question, you mentioned the private placement in the summer. Maybe you can just share the outcome of that and where your cash position is now and the runway you have looking forward.

Miranda Toledano
CEO, Entera Bio

We completed a $27.5 million PIPE. We announced that on July 27, 2026. You participated in it, thank you. Basically, the objective of that transaction was to fully fund EB613 through PDUFA. So we have cash runway into 2030, and that's publicly disclosed. Also in that time period, we also will be hopefully reading out some phase I SAD and MAD outcomes from EB612.

Vamil Divan
Analyst, Guggenheim

Okay. All right, so why don't we wrap it up there? Thanks again for joining us. Congrats on all the progress and-

Miranda Toledano
CEO, Entera Bio

Thank you.

Vamil Divan
Analyst, Guggenheim

I look forward to seeing everything moving forward.

Miranda Toledano
CEO, Entera Bio

Thank you, Vamil.

Vamil Divan
Analyst, Guggenheim

All right, great. Thank you.